I-Mab ADR (IMAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMAB POWR Grades
- Growth is the dimension where IMAB ranks best; there it ranks ahead of 91.72% of US stocks.
- The strongest trend for IMAB is in Growth, which has been heading down over the past 179 days.
- IMAB's current lowest rank is in the Quality metric (where it is better than 3.58% of US stocks).
IMAB Stock Summary
- IMAB's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.43 -- higher than merely 4.95% of US-listed equities with positive expected earnings growth.
- Over the past twelve months, IMAB has reported earnings growth of 14,959.68%, putting it ahead of 99.8% of US stocks in our set.
- Revenue growth over the past 12 months for I-MAB comes in at -92.84%, a number that bests only 1.15% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to I-MAB, a group of peers worth examining would be ERIC, LI, LPCN, VERU, and PACB.
- Visit IMAB's SEC page to see the company's official filings. To visit the company's web site, go to www.i-mabbiopharma.com.
IMAB Stock Price Chart Interactive Chart >
IMAB Price/Volume Stats
| Current price | $3.35 | 52-week high | $21.44 |
| Prev. close | $3.60 | 52-week low | $3.19 |
| Day low | $3.33 | Volume | 286,800 |
| Day high | $3.67 | Avg. volume | 496,098 |
| 50-day MA | $5.02 | Dividend yield | N/A |
| 200-day MA | $5.96 | Market Cap | 278.38M |
I-Mab ADR (IMAB) Company Bio
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Latest IMAB News From Around the Web
Below are the latest news stories about I-MAB that investors may wish to consider to help them evaluate IMAB as an investment opportunity.
I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday, March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST. |
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call TranscriptTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript March 8, 2023 Operator: Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call. . During today’s call, we will be making certain forward-looking statements, including statements regarding expected timing of clinical trials and results, regulatory activities, […] |
Q4 2022 TRACON Pharmaceuticals Inc Earnings CallQ4 2022 TRACON Pharmaceuticals Inc Earnings Call |
MSCI ESG Updated I-Mab to "A" RatingI-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (Morgan Stanley Capital International) ESG, following MSCIESG's most recent annual review, and such rating outperforms 66% peers among global biotech companies. |
We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
IMAB Price Returns
| 1-mo | -24.21% |
| 3-mo | -3.74% |
| 6-mo | -27.02% |
| 1-year | -82.85% |
| 3-year | -70.22% |
| 5-year | N/A |
| YTD | -19.86% |
| 2022 | -91.18% |
| 2021 | 0.51% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...